LipidBrick® is a novel range of proprietary cationic lipids dedicated to the formulation of LNPs for the development of mRNA-based vaccines and thera...
Lipid nanoparticles (LNP) have demonstrated high efficiency delivering RNA therapeutics in vivo. However, the properties of such nanoparticles obtained with conventional ionizable lipids are often hard to modulate, and especially their biodistribution profile. Such ionizable lipid-based nanoparticles often predominantly end up targeting the liver. One of the current challenges in the field consists of adjusting the particle chemical composition to the targeted application.
In this webinar, we discuss the characterization of a library of 10 innovative imidazolium-based cationic lipids as key component of cationic LNPs (cLNP). We disclose their chemical structures and demonstrate their efficacy generating LNPs through characterization of their hydrodynamic diameters, Zeta potentials, encapsulation efficiencies, their efficiency and in vivo biodistribution.
Learn more about how LipidBrick®, a library of novel Polyplus® proprietary cationic lipids, can address current challenges for mRNA therapeutics:
- Modulate lipid nanoparticles (LNPs) properties
- Improve transfection efficiency of LNPs in vitro and in vivo
- Expand the use of LNPs beyond the liver
- Enable for screening of best suited lipid to adapt the biodistribution of LNPs according to therapeutic applications